drugset
drugset / Trial / NCT03056599

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

NCT03056599 ↗

Phase 1 Completed 23 enrolled Presage Biosciences Fred Hutchinson Cancer Center · collabNorthwell Health · collabOregon Health and Science University · collabUniversity of Washington · collab
NaSingle-groupOpen-labelBasic science

Summary

This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.

Timeline

Start
2016-12-15
Primary completion
2021-07-22
Completion
2021-09-22

Outcome

Met primary endpoint

paper The primary objective was met, establishing CIVO's feasibility and safety. PMID 32299817 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody — Other
Subject Avapritinib Small molecule — Other
Subject Avelumab Monoclonal antibody — Other
Subject Bortezomib Small molecule — Other
Subject Docetaxel Small molecule — Other
Subject Doxorubicin Other / unclassified — Other
Subject Durvalumab Monoclonal antibody — Other
Subject Entrectinib Small molecule — Other
Subject Eribulin Small molecule — Other
Subject Gemcitabine Small molecule — Other
Subject Ipilimumab Monoclonal antibody — Other
Subject Larotrectinib Small molecule — Other
Subject Nivolumab Monoclonal antibody — Other
Subject Olaratumab Monoclonal antibody — Other
Subject Pembrolizumab Monoclonal antibody — Other
Subject Trabectedin Small molecule — Other
Subject aldesleukin Protein / enzyme biologic — Other
Subject interferon alfa-2b Protein / enzyme biologic — Other
Subject interferon gamma Protein / enzyme biologic — Other

Indications

soft tissue sarcoma